This company listing is no longer active
Myovant Sciences Dirección
Dirección controles de criterios 3/4
Información clave
Dave Marek
Chief Executive Officer (CEO)
US$6.2m
Compensación total
Porcentaje del salario del CEO | 12.0% |
Permanencia del CEO | 2.2yrs |
Participación del CEO | 0.1% |
Permanencia media de la dirección | 4.3yrs |
Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Dec 31 2022 | n/a | n/a | -US$184m |
Sep 30 2022 | n/a | n/a | -US$190m |
Jun 30 2022 | n/a | n/a | -US$166m |
Mar 31 2022 | US$6m | US$750k | -US$206m |
Dec 31 2021 | n/a | n/a | -US$228m |
Sep 30 2021 | n/a | n/a | -US$238m |
Jun 30 2021 | n/a | n/a | -US$284m |
Mar 31 2021 | US$10m | US$151k | -US$255m |
Compensación vs. Mercado: Dave's total compensation ($USD6.25M) is above average for companies of similar size in the German market ($USD2.40M).
Compensación vs. Ingresos: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Marek (57 yo)
2.2yrs
Permanencia
US$6,247,509
Compensación
Mr. David C. Marek, also known as Dave, has been Director of Myovant Sciences Ltd. since January 4, 2021 and served as its Principal Executive Officer. He had been Chief Commercial Officer of Axsome Therap...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
Principal Financial Officer | 1.5yrs | US$5.16m | 0% $ 0 | |
Chief Commercial Officer | 1.9yrs | US$3.47m | 0.022% $ 587.9k | |
General Counsel & Corporate Secretary | 5.7yrs | US$2.83m | 0% $ 0 | |
Director of Corporate Communications | no data | sin datos | sin datos | |
Senior Vice President of Human Resources | less than a year | sin datos | sin datos | |
Senior Vice President of Product Development | 6.6yrs | sin datos | sin datos | |
Chief Medical Officer | 5.7yrs | US$1.98m | 0.089% $ 2.3m | |
Head of Drug Safety & Pharmacovigilance | 5.7yrs | sin datos | sin datos | |
Senior VP of Pharmaceutical Operations & Development | 4.3yrs | sin datos | sin datos |
4.3yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: 71M's management team is considered experienced (4.3 years average tenure).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
Chairman of the Board | 4.5yrs | US$376.79k | 0% $ 0 | |
Independent Director | 6.3yrs | US$363.33k | 0% $ 0 | |
Director | 3.3yrs | US$341.79k | 0% $ 0 | |
Lead Independent Director | 4.7yrs | US$369.95k | 0% $ 0 | |
Non Independent Director | less than a year | sin datos | sin datos | |
Independent Director | 1.3yrs | US$567.05k | 0% $ 0 |
3.3yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: 71M's board of directors are considered experienced (3.3 years average tenure).